What happened with TXG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
10x Genomics helps researchers examine biological information in individual cells and locate it within tissue samples. Its Chromium platform supports single-cell analysis, while Visium and Xenium show where biological signals occur in tissue. Researchers buy instruments and the chips, slides and reagents used in experiments, with accompanying software to process and explore the data. Consumables provide most of the revenue, and Chromium instruments and consumables account for the majority of the business. Most consumables are designed specifically for its instruments, so continued experiment activity drives repeat purchases.
Customers include universities, government research institutions and biopharmaceutical companies; academic and government institutions account for the largest share of direct sales. A substantial part of revenue depends on customers supported by U.S. academic and government research funding, including NIH grants, so funding availability affects purchases. The core business serves research rather than clinical diagnosis. Selling products for diagnostic use would require applicable regulatory authorization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
10x Genomics hinges on research funding and repeat purchases of single-cell and spatial consumables, while privately held spatial rival Vizgen matters through both competition and patent royalties.
Bruker competes with 10x Genomics' Visium and Xenium for researchers' spending on tools that map tissue biology, but also pays 10x patent royalties under their settlement.
Illumina supplies researchers with the instruments and reagents that read genetic material prepared by 10x Genomics' single-cell and sequencing-based spatial workflows, tying both businesses to sequencing experiment volumes and research funding.
Quanterix competes for the tissue-profiling budgets that fund 10x Genomics' spatial platforms through its acquired Akoya business, which sells tools for imaging tissue biology.
Bio-Techne competes with 10x Genomics for researchers' spending on tests that locate molecular signals within tissue. Watch its spatial biology business rather than the whole Diagnostics and Spatial Biology segment, which also includes diagnostic products and liquid biopsy.
PacBio and 10x Genomics draw on the same genomics research budgets: PacBio sells instruments and consumables that read long stretches of DNA, while 10x sells platforms for analyzing individual cells. Researchers' use of PacBio for single-cell sequencing is the overlap to watch.
Cytek Biosciences and 10x Genomics depend on academic and biopharmaceutical researchers' cell-analysis budgets: Cytek sells systems that measure many cell markers using fluorescence, while 10x profiles cells' molecular contents. Cytek's consumables demand from installed instruments offers a view of ongoing cell-analysis activity.
Revvity shares 10x Genomics' exposure to academic funding and drug-discovery spending, selling cell, gene and protein research tools to laboratories that also buy 10x's single-cell and spatial platforms. Its Life Sciences business is the relevant signal, rather than its diagnostics sales to hospitals and medical laboratories.
Bio-Rad's Life Science business shares 10x Genomics' exposure to research laboratories' spending, selling instruments and reagents for analyzing cells and nucleic acids to laboratories that also use 10x platforms. Watch that business rather than total sales, which also include Clinical Diagnostics.
QIAGEN and 10x Genomics both depend on molecular research experiment volumes: QIAGEN sells tools to prepare samples and detect molecular information, while 10x sells single-cell and spatial analysis workflows. QIAGEN's consumables and related revenue is the useful comparison with 10x's recurring consumables demand.
Thermo Fisher shares 10x Genomics' exposure to academic and biotechnology research spending, selling instruments, reagents and laboratory supplies to laboratories that also buy 10x platforms. Demand from those research customers is more relevant to 10x than Thermo Fisher's broader hospital, industrial and pharmaceutical-services businesses.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher sells instruments, reagents and supplies to research labs, and its report will show whether customers it shares with 10x Genomics are still buying.
Focus on Thermo Fisher’s research-facing business, not just total sales, which also reflect hospital and industrial customers. Steady or rising research-related sales would suggest that some lab budgets shared with 10x Genomics remain supported. Weakness there would point to tighter purchasing by shared customers, but would not by itself prove that 10x’s sales are falling.
Fed Interest Rate Decision
10x Genomics’ rate decision has no stated direct path to its instrument and consumables sales or operating costs; it may matter only if the company seeks financing or through returns on its substantial cash and marketable securities.
Expected4.0%Last release4.0%
Higher rates can make new borrowing more expensive if 10x Genomics seeks financing, while lower rates can make it cheaper; rates may also affect returns on its cash and marketable securities, but the profile does not identify either as a main business driver.
Illumina Inc earningsILMN
Illumina sells instruments and reagents that read genetic material, and its report will show whether sequencing demand linked to some 10x Genomics workflows is active.
Read Illumina’s instrument sales alongside its consumables sales. Growth in both would indicate researchers are buying sequencing systems and using reagents to run experiments; weakness in both would suggest cooler sequencing activity, a less supportive backdrop for related 10x Genomics workflows. Illumina’s sales do not show how many of those experiments use 10x platforms.
Bruker Corporation earningsBRKR
Bruker competes with 10x Genomics in tools for spatial biology, and its report will show whether researchers are still spending on this category.
Focus on Bruker’s spatial-biology business, not its other activities. Rising sales would show that researchers are still funding tissue-analysis tools, but would not mean 10x Genomics won the same orders. Falling sales would point to pressure on those budgets and a weaker category backdrop for 10x’s Visium and Xenium platforms.
QIAGEN N.V. earningsQGEN
QIAGEN sells sample-preparation and molecular-testing tools to researchers, and its report offers a read on molecular experiment activity relevant to 10x Genomics’ consumables demand.
Focus on QIAGEN’s research-related consumables and related revenue, not just total company sales. Growth would suggest that molecular experiments are still driving repeat purchases, a supportive backdrop for 10x Genomics’ reagent demand. A decline would point to weaker demand for experiment supplies, but QIAGEN’s customers and products differ from 10x’s, so their sales are not interchangeable.
10x Genomics, Inc. earningsThis company
10x Genomics sells instruments and consumables, and this report will show whether researchers keep using its platforms and buying reagents to run experiments.
Read consumables revenue alongside reactions sold, then compare both with instrument revenue. Reactions sold are the company’s measure of consumables activity. Growth in both, with instrument revenue holding up, would show that experiment volume and demand for new systems are supporting the business. If reactions and consumables grow while instruments fall, existing customers are still running experiments but new-system sales are weaker. If reactions and consumables also decline, repeat use is not supporting the business.
